Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

The Lancet

Volumn 371, Issue 9630, 2008, Pages 2093-2100

  Galiè, N ^a   Rubin, LJ ^b   Hoeper, MM ^c   Jansa, P ^d   Al Hiti, H ^e   Meyer, GMB ^f   Chiossi, E ^g   Kusic Pajic, A ^g   Simonneau, G ^h  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d CHARLES UNIVERSITY   (Czech Republic)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^f Complexo Hospitalar Sta Casa de Porto Alegre ^*  (Brazil)

^g ACTELION PHARMACEUTICALS LTD   (Switzerland)

^h HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; SILDENAFIL;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; LIVER FUNCTION TEST; MULTICENTER STUDY; NAUSEA; PATIENT CODING; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; THORAX PAIN; WALKING; WORLD HEALTH ORGANIZATION;

EID: 45249119855     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60919-8     Document Type: Article

References (34)

1. Rubin L. Primary pulmonary hypertension. N Engl J Med 336 (1997) 111-117
2. Galie N, Rubin L, eds. Pulmonary arterial hypertension. Epidemiology, pathobiology, assessment and therapy. J Am Coll Cardiol 2004; 43: S1-90.
3. Galie N., Manes A., and Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61 (2004) 227-237
4. Farber H., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 (2004) 1655-1665
5. Davie N., Haleen S., Upton P., et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165 (2002) 398-405
6. Channick R., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
7. Rubin L., Badesch D., Barst R., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
8. Humbert M., Barst R., Robbins I., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24 (2004) 353-359
9. Galie N., Beghetti M., Gatzoulis M., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
10. Rubin L., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112 (1990) 485-491
11. Barst R., Rubin L., Long W., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
12. Badesch D., Tapson V., McGoon M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
13. Langleben D., Christman B., Barst R., et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 143 (2002) E4
14. Simonneau G., Barst R., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
15. Galie N., Humbert M., Vachiery J., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
16. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
17. Barst R., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
18. Barst R., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
19. Sastry B., Narasimhan C., Reddy N., and Raju B. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
20. Galie N., Ghofrani H., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
21. Barst R., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
22. McLaughlin V., Oudiz R., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
23. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
24. McLaughlin V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
25. Enright P., and Sherrill D. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158 (1998) 1384-1387
26. Ware J., Kosinski M., and Gandek B. SF-36 health survey: manual & interpretation guide (2000), Qualitymetric Inc, Lincoln, RI
27. Humbert M., Segal E., Kiely D., Carlsen J., Schwierin B., and Hoeper M. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30 (2007) 338-344
28. Chi G. Multiple testings: multiple comparisons and multiple endpoints. Drug Inf J 32 (1998) 1347S-1362S
29. European Agency for the Evaluation of Medicinal Products (EMEA). Points to consider on multiplicity issues in clinical trials (CPMP/EWP/908/99). http://www.emea.europa.eu/pdfs/human/ewp/090899en.pdf (accessed Feb 13, 2008).
30. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
31. Williams M., Handler C., Akram R., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27 (2006) 1485-1494
32. Barst R., Rubin L., McGoon M., Caldwell E., Long W., and Levy P. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
33. Frost A., Langleben D., Oudiz R., et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 43 (2005) 36-39
34. McKenna S., Doughty N., Meads D., Doward L., and Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 15 (2006) 103-115